TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Dec 31, 2024. Filed Feb 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Director and Officer Rule
10b5-1
Trading Arrangements
During the three months ended December 31, 2024, each of the following officers adopted a Rule
10b5-1
trading arrangement (as such term is defined in Item 408 of Regulation
S-K).
All trading plans are intended to satisfy the affirmative defense of Rule
10b5-1(c)
under the Exchange Act.
| Name and Title | Date | Action | Expiration Date | Maximum SharesSubject to Plan (1) |
|---|---|---|---|---|
| Richard D. Francis, President and CEO | November 15, 2024 | Adopted | March 6, 2025 | 279,109 |
| Richard Daniell, EVP, Head of European Commercial | November 19, 2024 | Adopted | March 7, 2025 | 287,741 |
| Dr. Eric Hughes, EVP, Global R&D and Chief Medical Officer | November 15, 2024 | Adopted | August 4, 2025 | 100,893 |
| Eli Kalif, EVP, Chief Financial Officer | November 29, 2024 | Adopted | June 13, 2025 | 111,525 |
| David R. McAvoy, EVP, Chief Legal Officer | November 15, 2024 | Adopted | March 6, 2025 | 16,741 |
| (1) | Certain plans include shares to be sold solely to cover tax withholding obligations. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.